CIMG Q1 Revenue Reflects Initial Impact of Business Expansion

Q1 revenue reflects the initial impact of the company's expansion into medicine-food homology products and computing power solutions. This growth primarily reflects early-stage commercialization and expansion of new business lines. Alice Wang, Chairman and CEO of CIMG, stated: "The company will continue to focus on the Asia market and deepen the dual-track layout of health consumer goods and computing power technology products. On the one hand, we will seek to expand the online and offline sales channels for maca series and homology of medicine and food series products, optimize product pricing and cost control, and improve the gross profit margin of core categories over time, although there can be no assurance that these efforts will be successful. On the other hand, we will increase R&D investment in computing power products, improve the industry-specific customized development of artificial intelligence data processing modules, further expand the enterprise customer base, and raise the revenue share of the computing power business. In terms of capital operation and compliant operations, the company will actively advance the follow-up financing plan and optimize the capital structure. At the same time, we will strictly abide by the Nasdaq listing rules and rectify the previous listing compliance issues. The company has filed an appeal against the Nasdaq delisting decision and will make every effort to maintain its listing status. In addition, the company will strengthen the construction of internal financial management and internal control systems, improve operational efficiency, and drive the company's transition from business transformation to profit growth."